Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.54 |
| ▸ | HDAC2 known ✓ | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.54 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722568 | 0.99 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL6937640 | 0.86 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| Water SCHEMBL28864249 | 0.85 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL20562049 | 0.82 | HDAC1 (0.72) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL8113734 | 0.81 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL29263701 | 0.80 | HDAC1 (0.72) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL18893638 | 0.77 | HDAC1 (0.50) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL967387 | 0.76 | HDAC2 (0.68) | HDAC1HDAC2HDAC8HDAC6L3MBTL1 | |
| SCHEMBL28665907 | 0.74 | CTSD (0.47) | — | |
| Hydrochloric Acid SCHEMBL28493007 | 0.73 | CTSD (0.61) | HDAC1HDAC2HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981752-B2 | Tumor associated monocyte/macrophage binding peptide and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150397-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute | 2024-05-09 | — | — | US | disclosed |
| US-20230173097-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2023-06-08 | — | — | US | disclosed |
| EP-2250278-B1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RES (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220175941-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2022-06-09 | — | — | US | disclosed |
| US-20220119450-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2022-04-21 | — | — | US | disclosed |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-03-01 | — | — | US | disclosed |
| CN-113490681-A | Bispecific extracellular matrix binding peptides and methods of use thereof | 塔图大学 | 2021-10-08 | — | — | CN | disclosed |
| US-11077212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-29 | — | — | US | disclosed |
| EP-1996607-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | The Burnham Institute for Medical Research (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1966234-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDES AND USES THEREOF | The Burnham Institute for Medical Research (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| US-7332277-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2008-01-10 | — | — | US | disclosed |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2007-09-20 | — | — | US | disclosed |
| WO-2007090194-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007076501-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070122835-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | HDAC1 3698/4885HDAC2 4478/4885HDAC3 2758/4885 |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTA | HDAC1 4387/4885HDAC2 4637/4885HDAC3 4278/4885 |
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | ESR2, PROKR1, CXCL12 | HDAC1 4503/4885HDAC2 4673/4885HDAC3 3772/4885 |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | SLC39A3, SLC39A11, CCL2 | HDAC1 2693/4885HDAC2 4427/4885HDAC3 2950/4885 |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | SERPINB1, TMPRSS15, HPN | HDAC1 1825/4885HDAC2 2840/4885HDAC3 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.